2024’s first Bayou City Bio Pulse of the year will take place at TMC’s Helix Park on February 20 from 4 – 6 p.m. This event will provide a great networking opportunity in the beautiful new TMC3 Collaborative Building, and will feature presentations from TMC Venture Fund and some of the top startups in the TMC ecosystem. 

The Texas Medical Center Venture Fund (TMCVF) is the venture capital arm of Texas Medical Center. TMCVF is a $50M evergreen venture fund that invests in early-stage innovation with a Houston nexus. With over 20 portfolio companies, and multiple successful exits, TMCVF invests across digital, med device, and therapeutics. TMCVF partners with extraordinary entrepreneurs who are shaping the future of health. 

The program will include an introduction from President and CEO of the Texas Medical Center, Bill McKeon, as well as presentations and a panel from the following TMCVF startup representatives:

• Tim Boire, PhD, the co-founder and CEO of Venostent, a Houston based clinical-stage medical device company. Venostent developed a bioabsorbable vascular wrap to help improve outcomes for hemodialysis patients. Venostent recently announced enrollment of its first subject in its SAVE-FistuaS Clinical Trial. Prior to Venostent, Tim developed this technology while getting his PhD at Vanderbilt and worked at Genzyme.
• Emma Fauss, PhD, MBA, the CEO and co-founder of Medical Informatics Corp. (MIC), a company that is using digital technology to help create a new standard of care through data. As a thought leader in healthcare analytics, Dr. Fauss is often called upon to contribute her perspective to the growing interest in remote patient monitoring and the application of data capture, analytics, machine learning and AI in patient care.
• Sarah Hein, PhD, the co-founder and CEO of March Biosciences, a Houston based biotech startup company. Sarah partnered with co-founder Max Mamonkin of Baylor College of Medicine to commercialize a clinical stage cell therapy for T-cell lymphoma. 
• Michael Torres, the co-founder and CEO of CrossBridge Bio, a Houston based biotech company developing novel antibody drug conjugate technology in collaboration with the Texas Therapeutics Institute at UTHealth. Prior to CrossBridge, Michael was co-founder of ReCode Therapeutics, a delivery platform company spun out of his UT-Southwestern laboratory which has raised over $340 million.  

This event will feature networking, drinks and hors d'oeuvres, and building tours. Registration is free.  

Register below to learn more about TMC Venture Fund and network with movers and shakers in Houston’s life sciences ecosystem.

Thank you to our event partners, BioHouston and Texas Medical Center.